Trials / Terminated
TerminatedNCT01194960
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Oxford BioMedica · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression. |
| DRUG | TroVax | Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37 |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2010-09-03
- Last updated
- 2020-10-19
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01194960. Inclusion in this directory is not an endorsement.